Efficacy and Safety of Young Health Plasma on Acute Stroke
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02913183 |
Recruitment Status : Unknown
Verified September 2016 by Xiao-Yi Xiong, Xinqiao Hospital of Chongqing.
Recruitment status was: Not yet recruiting
First Posted : September 23, 2016
Last Update Posted : September 23, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stroke | Drug: young Fresh Frozen Plasma Drug: old Fresh Frozen Plasma | Phase 2 |
This study will enroll 78 stroke patients who have been diagnosed with stroke and meet the inclusion criteria.
After successfully meeting initial screening criteria, investigators will contact the family, explain the study, and send a consent form for their review.
After that, patients will be given 2 unit/day young health plasma (young plasma exchange) over a course of 3 consecutive days, then investigators will make a neurofunctional assessment before and 7 days, 30 days and 90 days after young health plasma treatment. And Magnetic Resonance of the brain before, 7 days, 14 days and 90 days after young health plasma treatment.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 78 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Efficacy and Safety of Young Health Plasma on Acute Stroke |
Study Start Date : | October 2016 |
Estimated Primary Completion Date : | October 2017 |
Estimated Study Completion Date : | October 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: young Fresh Frozen Plasma
|
Drug: young Fresh Frozen Plasma
Blood plasma from healthy male donors aged 18-30 years old. |
Placebo Comparator: old Fresh Frozen Plasma
|
Drug: old Fresh Frozen Plasma
Blood plasma from healthy male donors aged 40-55 years old. |
- Changes in National Institutes of Health Stroke Scale (NIHSS) [ Time Frame: up to 90 days ]describe the clinical improvement at baseline, 7 days, 14 days, 30 days and 90 days
- Changes in modified Barthel Index [ Time Frame: up to 90 days ]describe the clinical improvement at baseline, 7 days, 14 days, 30 days and 90 days
- Changes in modified Rankin Scale [ Time Frame: up to 90 days ]describe the clinical improvement at baseline, 7 days, 14 days, 30 days and 90 days
- Changes in Glasgow coma scale [ Time Frame: up to 90 days ]describe the clinical improvement at baseline, 7 days, 14 days, 30 days and 90 days
- Changes in hematoma volume [ Time Frame: At baseline, 7 days, 14 days and 30 days after the onset ]
- Change in peripheral edema volume [ Time Frame: At baseline, 7 days, 14 days and 30 days after the onset ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years to 80 Years (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 65-80 years
- Clinical presentation of spontaneous intracerebral hemorrhage/ischemic stroke
- CT/MRI/MRA scan compatible with spontaneous intracerebral hemorrhage/ ischemic stroke
- Time to young plasma treatment < 72 h from symptom onset
- Glasgow Coma Score > 6 on initial presentation or improvement to a Glasgow Coma Score > 6 within the time frame for enrollment
- The first-ever primary supratentorial intracerebral basal ganglia hemorrhage 5-30ml
- Signed and dated informed consent is obtained
- TOAST: Large-artery atherosclerosis
Exclusion Criteria:
- Patients who will undergo surgical evacuation of intracerebral hemorrhage/ischemic stroke
- Inability to undergo neuroimaging with Magnetic Resonance
- Glasgow Coma Score < 6
- Significant past history of disability, modified Rankin Scale(mRS)≥1
- Primary intraventricular hemorrhage ICH due to coagulopathy (PT > 15 s or International Normalized Ratio > 1.3, Partial Thromboplastin Time > 36) or trauma
- Thrombocytopenia: platelet count <100 000
- Clinically significant hepatic disease as demonstrated by history, clinical exam (ascites, varices), or laboratory findings (LFTs >2x normal, coagulopathy as described)
- Comorbid conditions likely to complicate therapy including but not limited to the following: a history of New York Heart Association class II, III, or IV Congestive Heart Failure; end-stage acquired immune deficiency syndrome
- Known pregnancy, or positive pregnancy test, or breast feeding
- Malignancy (history of or active)
- Bradyarrhythmia and Atrioventricular Block
- Concomitant use with antineoplastic,immunosuppressive or immune modulating therapies
- Macular Edema
- Life expectancy of less than 90 days due to comorbid conditions
- Occurrences of secondary intracerebral hemorrhage/ischemic stroke
- Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, noncompliance, living in another state or any other cause

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02913183
Contact: Qing-Wu Yang, MD,PhD | yangqwmlys@hotmail.com | ||
Contact: Xiao-Yi Xiong, MD,PhD | xiongxy1989@hotmail.com |
Responsible Party: | Xiao-Yi Xiong, Medical Doctor, Xinqiao Hospital of Chongqing |
ClinicalTrials.gov Identifier: | NCT02913183 |
Other Study ID Numbers: |
XinqiaoH-01 |
First Posted: | September 23, 2016 Key Record Dates |
Last Update Posted: | September 23, 2016 |
Last Verified: | September 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Neurofunctional assessment including NIHSS, modified Barthel Index, modified Rankin Scale,and Glasgow coma scale, hematoma volume,and peripheral edema volume are to be shared. |
acute stroke young health plasma efficacy safety |
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |